STAT
NOVEMBER 12, 2024
The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into. But full trial data published in September showed Dato-DXd did not outperform standard chemotherapy on overall survival.
Express Pharma
SEPTEMBER 18, 2024
billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. Pluvicto is indicated for metastatic CRPC (mCRPC) patients previously treated with ADT and taxane chemotherapy. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 6, 2022
Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.
STAT
NOVEMBER 12, 2024
The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily. AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it nearly double revenue to $80 billion by 2030.
Express Pharma
JANUARY 22, 2025
The company aims to reduce the toxic effects of chemotherapy and chances of cancer relapse improving the quality of lives of patients suffering from cancer. By 2025, the contribution of the Indian biotechnology industry to the global biotechnology market is expected to grow to 19 per cent.
Express Pharma
SEPTEMBER 19, 2023
Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. per cent from 2021 to 2030. With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles. billion in 2021 and is projected to reach $536.01
Express Pharma
JUNE 1, 2023
Venus Remedies secured a marketing authorisation from the largest market in the Gulf Cooperation Council (GCC) region for Docetaxel, a chemotherapy drug. The $102-billion global Docetaxel market is projected to grow to $184 billion by year 2030 at a CAGR of 10.22 The marketing approval for Docetaxel from Saudi Arabia, a $7.8-billion
Expert insights. Personalized for you.
278 
Let's personalize your content